Pharmacokinetic Evaluation of Colistimethate Sodium in Treating Serious Infections by Aerobic Gram-Negative Pathogens in Patients with Limited Treatment Options

The primary objective of this study is to evaluate the **pharmacokinetics** of colistimethate sodium in the treatment of serious infections caused by selected aerobic gram-negative pathogens in patients with limited treatment options. Understanding the pharmacokinetics is clinically relevant as it provides insights into the absorption, distribution, metabolism, and excretion of the drug, which is crucial for optimizing dosing regimens and improving therapeutic outcomes in this patient population.

The clinical trial involves participants diagnosed with **serious infections** caused by selected aerobic gram-negative pathogens, specifically targeting patients with limited treatment options. The study population includes both male and female subjects, with an age range starting from 18 years and above. The trial also considers vulnerable populations, although specific details regarding the selection process or lifestyle considerations such as diet and physical activity are not provided. The sponsor has not disclosed the total number of participants involved in the study. Key inclusion or exclusion criteria have not been specified, and the general health status of the participants is not detailed in the available data.

The clinical trial is designed to evaluate the **pharmacokinetics** of colistimethate sodium in patients suffering from serious infections caused by selected aerobic gram-negative pathogens, particularly in those with limited treatment options. This study is a Phase 3 trial, which is randomized, double-blind, and controlled to ensure the reliability and validity of the results. The trial is expected to commence recruitment on June 18, 2025, and is projected to conclude by July 20, 2025.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit, where eligibility criteria will be assessed. This visit is crucial for determining the suitability of participants for the trial. Following the screening, participants will attend scheduled follow-up visits, which are designed to monitor the safety and efficacy of the treatment, as well as to collect necessary pharmacokinetic data. The sequence and frequency of these visits will be determined by the study protocol. The trial will culminate in an end-of-study visit, where final assessments will be conducted to evaluate the overall outcomes and any long-term effects of the treatment.

The expected duration of participant involvement in the trial will be aligned with the overall trial timeline, from the initial screening to the end-of-study visit. Participants may be subject to early termination from the study if they experience adverse events that compromise their safety, if they withdraw consent, or if they fail to comply with the study protocol. The trial is structured to ensure that all procedures are conducted in accordance with ethical standards and regulatory requirements, providing a comprehensive assessment of the investigational product's pharmacokinetic profile in the target patient population.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available. Additionally, details about drug administration, dosing schedules, and participant compliance monitoring are not included in the source data. As such, no further information can be offered regarding the substances or treatments involved in this clinical trial.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on June 18, 2025, with an estimated end date of July 20, 2025. The efficacy assessment will be conducted in accordance with the trial's protocol, which is structured to ensure rigorous evaluation of the treatment's impact. Although specific endpoints and methods for measuring efficacy are not detailed, the trial will adhere to standard practices for Phase 3 studies, which typically involve comprehensive data collection and analysis to determine the treatment's effectiveness. The trial's design will likely include the use of validated scales, laboratory tests, or patient-reported outcomes to measure efficacy, consistent with the objectives of a Phase 3 trial. The results will be analyzed to provide insights into the treatment's potential benefits and inform future clinical decisions.